Bristol-Myers Squibb Company (BMY)

Receivables turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	48,300,000	47,435,000	46,509,000	45,534,000	45,006,000	44,935,000	45,187,000	45,848,000	46,159,000	46,738,000	47,144,000	46,960,000	46,385,000	45,468,000	44,384,000	42,810,000	42,518,000	39,395,000	34,862,000	31,006,000
Receivables	US$ in thousands	10,747,000	11,026,000	11,423,000	10,447,000	10,921,000	10,304,000	10,112,000	10,054,000	9,886,000	9,613,000	9,054,000	8,511,000	9,369,000	9,245,000	9,017,000	8,660,000	8,501,000	8,062,000	7,855,000	8,290,000
Receivables turnover		4.49	4.30	4.07	4.36	4.12	4.36	4.47	4.56	4.67	4.86	5.21	5.52	4.95	4.92	4.92	4.94	5.00	4.89	4.44	3.74

December 31, 2024 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $48,300,000K ÷ $10,747,000K
= 4.49

The receivables turnover ratio measures how efficiently a company is able to collect payments from its customers. A high receivables turnover ratio indicates that the company is collecting payments quickly, while a low ratio suggests that it may be facing challenges with collections.

Analyzing Bristol-Myers Squibb Company's receivables turnover based on the provided data shows a fluctuating trend over the quarters. The ratio ranged from a low of 3.74 as of March 31, 2020, to a high of 5.52 as of March 31, 2022. Generally, an increasing trend in the receivables turnover ratio is considered favorable as it indicates that the company is improving its collection efficiency.

It's worth noting that the ratio peaked at 5.52 as of March 31, 2022, suggesting a significant improvement in the company's ability to collect receivables efficiently. However, the ratio decreased in subsequent quarters, indicating potential challenges in collections. The ratio remained relatively stable between 4.07 and 5.21 from June 30, 2022, to June 30, 2024, showcasing some inconsistency in the collection process.

Overall, Bristol-Myers Squibb Company's receivables turnover ratio demonstrates a mix of fluctuations and improvements over the quarters. Continued monitoring of this ratio is essential to ensure efficient management of receivables and maintain healthy cash flow levels.